ReviewCurrent rheumatology reports2002
Idiopathic inflammatory myopathy: autoantibody update.
Review in Current rheumatology reports, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 50 citations in OpenAlex.
- Correlation study between clinical phenotypes and autoantibodies in systemic sclerosis in Southwest China.Medicine · 2025Observational
- Recurrent Temporal Infections: The Link to Systemic Lupus Erythematosus.The American journal of case reports · 2023Article
- Review
- Antisynthetase syndrome: A distinct disease spectrum.Journal of scleroderma and related disorders · 2020Review
- Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.Rheumatology international · 2019Review
- Bench to bedside review of myositis autoantibodies.Clinical and molecular allergy : CMA · 2018Review
- Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature.Pediatric rheumatology online journal · 2017Review
- Anti-MDA5-Positive Dermatomyositis Presenting as Fever of Unknown Origin.Journal of general internal medicine · 2016Article
- Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.Rheumatology international · 2016Article
- Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy.Acta neuropathologica communications · 2014Article
- Paraneoplastic dermatomyositis with carcinoma cervix: a rare clinical association.Case reports in dermatological medicine · 2014Article
- Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes.Journal of proteome research · 2011Article
- The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.Journal of the American Academy of Dermatology · 2011Article
- Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.Journal of neurology · 2011Review
- Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease.Arthritis and rheumatism · 2009Article
- Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center.Journal of the American Academy of Dermatology · 2007Article
- Myositis specific autoantibodies.Current rheumatology reports · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several defined, specific autoantibodies have been associated with polymyositis and dermatomyositis. These include autoantibodies to at least six of the aminoacyl-transfer-ribonucleic-acid synthetases; to the signal recognition particle; to the protein complexes labeled Mi-2 and PM-Scl; and several autoantibodies, such as anti-U1nRNP and anti-Ro/SSA, that have recognized associations with other conditions. These autoantibodies are a continuing area of interest. Recent studies have involved the clinical implications of these autoantibodies, and their potential significance for etiology and pathogenesis of the disease. This report will review recent studies of myositis autoantibodies and their clinical associations, both extramuscular features, such as interstitial lung disease and aspects of the myositis itself. New myositis autoantibodies continue to emerge, which may have clinical utility. Several have been associated with dermatomyositis, including juvenile dermatomyositis, which has a low frequency of traditional myositis autoantibodies. There is also new information regarding the antigenic targets of anti-Mi-2 and anti-PM-Scl, two of the earliest recognized myositis autoantibodies. New evidence over the past few years has challenged old concepts of the relationship of autoantibodies to the pathogenesis of myositis, and has suggested potential new mechanisms for the origin of the associated autoantibodies. Despite this progress, the reason for production of the autoantibodies and their role in tissue injury remain unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.